Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, recently announced that it has launched ZYFLO CR™ (zileuton) extended-release tablets with its marketing partner, Critical Therapeutics, Inc. ZYFLO CR™ offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older. “We are excited to partner with Critical Therapeutics to bring a twice-daily formulation of ZYFLO® (zileuton tablets) to the many patients affected by chronic asthma,” said Christy Taylor, Executive Vice President, Sales, Marketing and Business Development at DEY. “Our collaboration with Critical Therapeutics and the launch of ZYFLO CR(TM) demonstrate our commitment to developing and marketing innovative respiratory therapeutics to enhance patients’ lives.” In March 2007, Critical Therapeutics and DEY entered into an agreement for the co-promotion of ZYFLO CR™ and ZYFLO®, the immediate-release formulation of zileuton. DEY’s sales force began promoting ZYFLO® on April 30, 2007. ZYFLO CR™ received approval from the U.S. Food and Drug Administration on May 31, 2007.